Ribose-adenine dimer prodrug compound as well as preparation method and pharmaceutical application thereof
By synthesizing ribose-adenine dimer prodrug compounds, the problem of their polarity being difficult to pass through the cell membrane is solved, and the application in antiviral and anti-tumor drugs is achieved, especially in the treatment of influenza viruses, showing low cells Toxicity and good anti-activity.
Patent Information
- Application Number
- CN202411223429.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-12-06
AI Technical Summary
Due to their high polarity, ribose-adenine dimers are difficult to pass through the cell membrane, resulting in limited use in antiviral and anti-tumor drugs.
Design and synthesize a ribose-adenine dimer prodrug compound, whose structural formulas are the same or different, and X and Y are independently selected from -H, C1-10 linear alkyl, halogen, -CN , -N3, -OH, -NH2, Z is selected from H, F, Me, N3, CN, C2-5 alkynyl, and Compound 10 is obtained through a specific synthetic route, used as an active ingredient in the treatment of influenza viruses.
Compound 10 has very low cytotoxicity and shows good anti-influenza activity, with good application prospects in the treatment of influenza viruses.
Smart Images

Figure CN119080858A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of organic chemical synthesis, and in particular to ribose-adenine dimer prodrug compounds, preparation methods thereof and applications thereof in antiviral and antitumor drugs. Background Art
[0002] Nucleotides are widely found in animals and plants, have important biological functions, and participate in almost all biochemical reaction processes in organisms. Nucleoside drugs are widely used in the fields of tumors, infectious diseases (viruses such as HSV, HIV, HBV, HCV or fungal infections). Nearly 50% of the antiviral drugs currently used are nucleoside drugs. Their targets are mostly DNA polymerase or RNA reverse transcriptase. Nucleoside drugs simulate the structure of natural nucleosides, competitively act on the enzyme active center, embed into the synthesizing DNA or RNA chain, and interfere with nucleic acid metabolism.
[0003] After entering the cell, nucleoside drugs undergo three-step phosphorylation under the action of enzymes to obtain triphosphate derivatives with biological activity and exert their efficacy. Among them, monophosphorylation is the rate-limiting step, so monophosphate or phosphate groups are usually directly introduced into nucleoside drugs. Ribose-adenine dimer pRib-AMP is a newly discovered immunoactive small molecule in natural plants. It is a nucleoside signaling molecule produced by TNL through enzymatic reactions. However, due to its high polarity, it is difficult to pass through the cell membrane. In order to solve the drug-like problem in the design of this type of drug, the prodrug strategy is widely used in the research and development of nucleoside drugs. Summary of the invention
[0004] In order to overcome the above technical defects, the present invention aims to provide a ribose-adenine dimer prodrug compound; another purpose is to provide a synthesis method thereof and its application in antiviral and antitumor drugs.
[0005] To achieve the purpose of the present invention, the specific technical scheme is as follows:
[0006] 1. The ribose-adenine dimer prodrug compound of the present invention has the general structural formula:
[0007]
[0008] R 1 and R 2 The same or different, wherein X and Y are independently selected from: -H, C1-10 straight chain alkyl, halogen, -CN, -N3, -OH, -NH2, and Z is selected from H, F, Me, N3, CN, C2-5 alkynyl.
[0009] Preferably: X and Y are independently selected from -NH2, -H; Z is selected from H, F, Me.
[0010] More preferably: X is selected from -NH2, Y is selected from: -H; Z is selected from H.
[0011] The following compounds are preferred:
[0012] (1)R 1 =R 2 =H; X=NH2, Y=H; Z=H.
[0013] (2) X=NH2, Y=H; Z=H. (3)
[0015]
[0016] X=NH2, Y=H; Z=H.
[0017] The pharmaceutical application of the ribose-adenine dimer prodrug compound is to use it as an active ingredient in a drug for treating influenza.
[0018] The present invention also provides a method for preparing the ribose-adenine dimer prodrug compound as described above, and the synthetic route is as follows:
[0019]
[0020] The specific synthesis steps are as follows:
[0021] The 3,5-hydroxyl groups of compound 1 were selectively protected with 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane to obtain compound 3. The 2-hydroxyl group of compound 3 and the 1-hydroxyl group of compound 4 underwent glycosylation to obtain compound 5. After removing the benzoyl protection, the 5-hydroxyl group of compound 6 was selectively reacted with N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphoryl]-L-alanine isopropyl ester to obtain compound 8. After removing the silicon protecting group with tetrabutylammonium fluoride at 0°C, the compound was reacted again with N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphoryl]-L-alanine isopropyl ester to obtain the ribose-adenine dimer prodrug compound 10.
[0022] Advantages of the present invention: The ribose-adenine dimer prodrug compound has very low cytotoxicity and good anti-influenza activity, and has good application prospects in treating influenza virus. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 is the compound 3 of the present invention 1 H NMR spectrum;
[0024] Figure 2 is the compound 3 of the present invention 13C NMR spectrum;
[0025] Figure 3 is the compound 5 of the present invention 1 H NMR spectrum;
[0026] Figure 4 is the compound 5 of the present invention 13 C NMR spectrum;
[0027] Figure 5 is the compound 6 of the present invention 1 H NMR spectrum;
[0028] Figure 6 is the compound 6 of the present invention 13 C NMR spectrum;
[0029] Figure 7 is the compound 8 of the present invention 1 H NMR spectrum;
[0030] Figure 8 is the compound 8 of the present invention 31 P NMR spectrum;
[0031] Fig. 9 is the compound 9 of the present invention 1 H NMR spectrum;
[0032] Fig.10 is the compound 9 of the present invention 31 P NMR spectrum;
[0033] Fig.11 is the compound 10 of the present invention 1 H NMR spectrum;
[0034] Fig.12 is the compound 10 of the present invention 31 P NMR spectrum;
[0035] Fig.13 is a bar graph of the cytotoxicity of compound 10 of the present invention;
[0036] Fig.14 is the Western blots of the compound 10 of the present invention and the blank control DMSO;
[0037] Fig.15 is a bar graph of the anti-influenza virus activity of compound 10 of the present invention and blank control DMSO;
[0038] Fig.16 It is a bar graph of the anti-influenza virus activity of the compound 10 of the present invention and the blank control DMSO supernatant. DETAILED DESCRIPTION
[0039] The technical solution of the present invention is further described in detail below through specific implementation methods, but the protection scope of the present invention is not limited thereto. Unless otherwise specified, the technical means used in the following embodiments are conventional means well known to those skilled in the art.
[0040] Main instruments and chemical reagents
[0041] NMR spectrometer: Bruker Ascend TM 400; high-resolution mass spectrometer: Bruker MicrOTOF-Q II mass spectrometer; infrared spectrometer: Zhiwei Smart Fourier transform infrared spectrometer (Tianjin Gangdong Technology Co., Ltd.); three-purpose ultraviolet analyzer: ZF-6 (Shanghai Gaopeng Technology Co., Ltd.); melting point meter for determination: XT4A microscopic melting point determination instrument (Beijing Keyi Electro-Optical Instrument Factory).
[0042] The raw materials and solvents used in the implementation of the present invention are all purchased from commercial channels.
[0043] Example 1: Synthesis of ribose-adenine dimer prodrug compounds
[0044]
[0045] The specific synthesis steps of ribose-adenine dimer prodrug compounds are as follows:
[0046] 1) Weigh compound 1 (30.00 g, 80.84 mmol) and dissolve it in 200 mL of pyridine. Add 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (26.77 g, 84.88 mmol) at 0°C. The reaction solution continues to react at this temperature for 16 h. After TLC detection, the reaction is complete, and the pyridine is directly concentrated and evaporated to dryness. Silica gel column chromatography is used for separation. The eluent is first PE / EtOAc=2:1 to separate the residual pyridine, and then CH2Cl2 / MeOH 20:1 is used to separate the white solid compound 3 (37.00 g, 60.33 mmol). The yield is 75%. White solid, 75% yield, R f =0.4[dichloromethane / methanol (20:1)]; 1H NMR (400MHz, CDCl3) δ9.29 (s, 1H), 8.73 (s, 1H), 8.15 (s, 1H), 8.02 (d, J = 7.3Hz, 2H), 7.58 (t, J = 7.2Hz, 1H), 7.49 (t, J = 7.8Hz, 2H),6.02(s,1H),5.08(dd,J=7.4,5.6Hz,1H),4.61(d,J=5.4Hz,1H),4.15–4.01(m,3H),3.45(s,1H),1.12–0.99(m,28H)ppm; 13 C NMR (100MHz, CDCl3) δ164.8,152.8,151.1,149.8,142.1,133.8,132.9,128.9,128.0,123.7,89.9,82.3,75. 2,70.7,61.6,17.54,17.46,17.44,17.38,17.2,17.09,17.07,17.0,13.4,13.1,12.9,12.7ppm; ESI-MS[M+H] + for C 29 H 44 N5O6Si2,calcd 614.3,found 614.0.
[0047] 2) Weigh 1-acetoxy-2,3,5-tribenzoyloxy-1-β-D-ribofuranose (32.92 g, 65.25 mmol) and dissolve it in 60 mL 1,2-dichloroethane. Add tin tetrachloride (23.37 g, 89.72 mmol, 10.34 mL) dropwise at 0°C under nitrogen protection. After the reaction solution reacts at this temperature for 10 minutes, a solution of compound 3 (25.00 g, 40.78 mmol) in 1,2-dichloroethane (100 mL) is added dropwise to the above solution. The reaction solution continues to react at 0°C for 30 hours. After the reaction is complete by TLC detection, 100 mL of saturated sodium bicarbonate aqueous solution is added to quench, diatomaceous earth is filtered, washed with dichloromethane, the filtrate is concentrated, and the silica gel column chromatography is used for separation. The eluent is PE / EtOAc 1:1 to separate the white solid compound 5 (30.19 g, 28.55 mmol) with a yield of 70%. White solid, 70% yield, R f =0.35 [petroleum ether / ethyl acetate (2:1)]; 1H NMR (400MHz, CDCl3) δ9.11(s,1H),8.72(s,1H),8.13(s,1H),8.02–7.95(m,6H),7.88(d,J=7.2Hz,2H),7.60–7.56( m,2H),7.53–7.47(m,4H),7.42(t,J=8.0Hz,2H),7.36–7.29(m,4H),6.08(s,1H),5.97(dd,J=6.5,5.0Hz,1H),5.89( d,J=4.9Hz,1H),5.82(s,1H),4.96(dd,J=9.2,4.5Hz,1H),4.88(d,J=4.6Hz,1H),4.82–4.73(m,2H),4.66(dd,J=11 .2,5.9Hz,1H),4.18(d,J=13.3Hz,1H),4.12(d,J=9.2Hz,1H),4.01(dd,J=13.3,2.4Hz,1H),1.08–0.96(m,28H)ppm; 13 C NMR (100MHz, CDCl3) δ166.2,165.5,165.1,152.9,150.9,149.5,142.0,133.9,133 .62,133.56,133.3,132.8,129.9,129.8,129.7,129.2,129.0,128.6,128.50,128 .49,128.0,123.6,105.8,89.0,81.5,79.7,78.7,75.7,72.7,70.0,65.5,59.8,17 .5,17.44,17.39,17.3,17.2,17.0,16.9,13.4,13.0,12.9,12.7ppm; ESI-MS[M+H] + for C 55 H 64 N5O 13 Si2,calcd 1058.4,found1058.2.
[0048] 3) Compound 5 (25.00 g, 23.64 mmol) was weighed and dissolved in 50 mL of ammonia methanol solution. After reacting at room temperature for 24 h, it was directly concentrated and evaporated to dryness. The eluent was first CH2Cl2 / MeOH 30:1 to separate the intermediate, and then CH2Cl2 / MeOH 10:1 to separate the white solid compound 6 (6.50 g, 10.14 mmol), with a yield of 43%. White solid, 43% yield, R f =0.3[dichloromethane / methanol (10:1)]; 1H NMR (400MHz, CD3OD) δ8.25(s,1H),8.16(s,1H),6.03(s,1H),5.29(s,1H),4.67(dd,J=9.2,4.4Hz,1H),4.62(d,J=4.4Hz,1H),4.47(dd,J=8.0 ,4.8Hz,1H),4.23(d,J=13.2Hz,1H),4.12(d,J=9.2Hz,1H),4.07–4.02(m,2H),3.97-3.94(m,2H),3.73–3.69(m,1H),1.11–1.00(m,28H)ppm; 13 C NMR (100MHz, CD3OD) δ157.4,153.8,149.0,139.9,120.7,108.1,90.5,84.8,83.0,78.3,76.4,70 .8,70.7,62.0,61.2,18.0,18.0,17.9,17.8,17.6,17.5,17.4,14.6,14.2,13.8ppm; ESI-MS[M+H] + forC 27 H 47 N5O9Si2,calcd642.2985,found 642.2985.
[0049] 4) Weigh compound 6 (1.00 g, 1.56 mmol) and pentafluorophenol phosphate phenoxy intermediate (0.85 g, 1.87 mmol) in a 50 mL round-bottom flask, dry by rotary evaporation at 50 °C for 30 min (to remove the residual solvent in the raw material), and dissolve it in 20 mL of anhydrous tetrahydrofuran after cooling, evacuate and protect with N2. t BuMgCl (1M in THF, 3.12mmol, 3.12mL) was slowly added dropwise to the above solution, and the mixture was stirred at room temperature after 10min. After 12h, the reaction solution was directly dried by spin drying and separated by silica gel column chromatography. The eluent was first PE / EAOAc 2:1 to separate the pentafluorophenol phosphate phenoxy intermediate, and then CH2Cl2 / MeOH 10:1 to separate the white solid compound 8 (0.68g, 0.75mmol). 262mg of raw material was recovered, and the yield was 65%. White solid, 65% yield, R f =0.6[dichloromethane / methanol (10:1)]; 1H NMR (400MHz, CDCl3) δ8.27(s,1H),8.13(s,1H),7.30–7.28(m,2H),7.20-7.17(m,2H),7.12(t,J=7. 2Hz,1H),6.06–6.02(m,3H),5.34(s,1H),4.98–4.92(m,2H),4.86(dd,J=8.8,4.8Hz,1H),4.57(d,J= 4.8Hz,1H),4.46–4.43(m,1H),4.31–4.27(m,2H),4.20–4.19(m,1H),4.17–4.12(m,2H),4.08–4.05 (m,1H),4.02–3.98(m,2H),1.36(d,J=7.2Hz,3H),1.18(s,3H),1.16(s,3H),1.08–1.04(m,28H)ppm, 31 PNMR(162MHz, CDCl3)δ3.93; ESI-MS[M+K] + for C 39 H 63 N6O 13 PSi2,calcd 950.3434,found950.3339.
[0050] 5) Weigh compound 8 (330 mg, 0.36 mmol) and dissolve it in 10 mL of tetrahydrofuran. Add TBAF (1 Min THF, 0.76 mmol, 0.76 mL) at -60 °C. After reacting at this temperature for 1 h, add 1 mL of saturated sodium bicarbonate aqueous solution to quench, directly concentrate and evaporate to dryness, separate by silica gel column chromatography, and use CH2Cl2 / MeOH 10:1 as eluent to separate the raw material and the intermediate, and then change to CH2Cl2 / MeOH 5:1 to separate the white solid compound 9 (210 mg, 0.31 mmol), with a yield of 86%. White solid, 86% yield, R f =0.35 [dichloromethane / methanol (5:1)]; 1H NMR (400MHz, DMSO-d6) δ8.34(s,1H),8.13(s,1H),7.37–7.32(m,4H),7.20-7.13(m,3H),6.05(d,J=5.2Hz,1H),5.98(dd,J =12.4,10.4Hz,1H),5.36(dd,J=6.8,4.8Hz,1H),5.30(d,J=5.6Hz,1H),5.20(d,J=4.0Hz,1H),5.05(d,J=6.4Hz,1H),4.91 (s,1H),4.88–4.81(m,1H),4.73(t,J=5.2Hz,1H),4.38(q,J=4.8Hz,1H),4.04–3.98(m,1H),3.94(q,J=4.0Hz,1H),3.91–3 .77(m,4H),3.69–3.61(m,2H),3.56–3.51(m,1H),1.23(d,J=6.8Hz,3H),1.14(d,J=2.8Hz,3H),1.13(d,J=2.8Hz,3H)ppm, 31 P NMR(162MHz,DMSO-d6)δ3.85; ESI-MS[M+H] + for C 27 H 37 N6O 12 P,calcd 669.2280,found669.2280.
[0051] 6) Weigh compound 9 (150 mg, 0.22 mmol) and pentafluorophenol phosphate phenoxy intermediate (102 mg, 0.22 mmol) into a 50 mL round-bottom flask, dry by rotary evaporation at 50 °C for 30 min (to remove the residual solvent in the raw material), and dissolve it in 10 mL of anhydrous tetrahydrofuran after cooling, evacuate and protect with N2. t BuMgCl (1M in THF, 0.45mmol, 0.45mL) was slowly added dropwise to the above solution, and after 10min, the mixture was stirred at room temperature. After 12h, the reaction solution was directly dried by spin drying and separated by silica gel column chromatography. The eluent was first PE / EAOAc 2:1 to separate the pentafluorophenol phosphate phenoxy intermediate, and then CH2Cl2 / MeOH 10:1 to separate the white solid compound 10 (85mg, 0.09mmol). 43mg of the raw material was recovered, and the yield was 56%. White solid, 56% yield, R f =0.5[dichloromethane / methanol (10:1)]; 1H NMR(400MHz, CDCl3)δ8.25(s,1H),8.13(s,1H),7.24–7.20(m,4H),7.17–7.13(m,4H),7.06(q,J=7.2Hz,2H),6.2 9(s,2H),6.17(d,J=4.8Hz,1H),5.44(t,J=10.8Hz,1H),5.12(s,1H),4.97–4.84(m,3H),4.81(t,J=4.4Hz,1H),4. 69–4.63(m,2H),4.38–4.34(m,1H),4.29–4.25(m,2H),4.13–4.09(m,3H),4.08(m,1H),3.99–3.85(m,3H),1.32(d ,J=6.8Hz,3H),1.25(d,J=6.8Hz,3H),1.16(s,3H),1.15(s,3H),1.12(d,J=6.4Hz,3H),1.08(d,J=6.0Hz,3H)ppm, 31 P NMR (162MHz, CDCl3) δ3.87,3.26; ESI-MS[M+H] + for C 39 H 53 N7O 16 P2,calcd 938.3097,found 938.3098.
[0052] Example 2: Study on the anti-influenza virus activity of compound 10 synthesized in Example 1 of the present invention
[0053] 2.1 Cytotoxicity test of compound 10 of the present invention on A549 cells
[0054] In order to verify the anti-influenza virus activity of the compound 10 synthesized by the present invention, the cytotoxicity of the compound 10 was first tested. The specific experimental method is as follows: A549 cells were plated into a 96-well cell plate, and different concentrations of the compound 10 of the present invention (dissolving agent is DMSO) were added when the cell density was about 80% (marked as group #2). After 48 hours, the cell viability was detected by CCK-8 assay (CCK-8 assay kit purchased from Glpbio), which is specifically described as follows: 10uL of CCK-8 reagent was added to each well, and then the cells were returned to the cell culture incubator for incubation for 2 hours, and OD450 was detected, and the cell viability percentage was converted according to its absorbance.
[0055] Compound stock solution preparation and storage: DMSO was diluted to 10 mM or 20 mM and stored at -20°C; after the stock solution was thawed, it was diluted with cell culture medium DMEM / 10% FBS / 1% Pen / Strep.
[0056] The results of the cytotoxicity experiment of compound 10 on A549 cells showed that the cell viability was above 90% at a concentration of 500uM, as shown in Table 1 and the attached Fig.13 Bar chart.
[0057] Table 1 Cell viability of A549 cells at different concentrations of compound 10 of the present invention
[0058] Concentration (μM) Cell survival rate (%) 0 100% 250 93.64% 500 90.91% 1000 87.70% 2000 88.83% 4000 76.03%
[0059] 2.2 In vitro anti-influenza effect of compound 10
[0060] In order to further verify the anti-influenza virus activity of the compound 10 of the present invention, the in vitro anti-influenza virus activity of the compound 10 was tested. The specific experimental method is as follows: A549 cells were plated in a 12-well cell plate, the culture medium was discarded when the cell density was about 80%, the cells were washed once with PBS, the PR8 (H1N1) influenza virus was diluted to MOI = 0.05 with serum-free DMEM / F12 medium, 500uL of virus dilution was added to each well, and infection was carried out at 37°C for 1 hour. After the infection was completed, the supernatant was discarded, the cells were washed twice with PBS, and then 1% serum DMEM / F12 medium with 2μg / mL TPCK-trypsin (including DMSO control or 500uM compound 10 of the present invention (marked as group #2)) was added, and the cells were partially lysed after 24 hours for Western blots detection, and the supernatant was collected for TCID50 detection. Western blots were used to detect the most abundant protein M1 in influenza virus, which reflects the replication level of influenza virus in cells. The results showed that the M1 protein in the #2 treatment group was significantly lower than that in the DMSO control group. The protein grayscale value was analyzed using image J (see Appendix Fig.14 ).
[0061] 50% tissue culture infection dose (TCID50) refers to the virus dilution that can cause cytopathic effects in half of the monolayer cell wells. This method can be used to detect the infectious virus content in the supernatant. The specific steps are as follows:
[0062] 1. One day before the experiment, MDCK cells were inoculated into a 96-well microplate and the TCID50 test was performed after the cells grew into a monolayer.
[0063] 2. Serially dilute the virus sample to be tested 10-fold using serum-free DMEM medium.
[0064] 3. Use a pipette to discard the culture medium in each well of the microplate, and wash the microplate twice with sterile PBS. Use a micropipette to inoculate each dilution of the virus solution into one vertical row (8 wells) of a 96-well cell plate in the order of dilution, 0.1 mL per well, and add only 100 μL of DMEM culture medium to the last row of cells as a negative control, and culture in a 37°C, 5% CO2 incubator.
[0065] 4. Observe and record the cytopathic effect every day, and use the appearance of cytopathic effect as an infection indicator. However, CPE is usually difficult to observe, so TCID50 is calculated by measuring the results of the hemagglutination test. Specific steps: 72 hours after culture, freeze the 96-well plate at -80℃, and then thaw the 96-well plate in a 37℃ CO2 incubator. After thawing, draw 50μL of culture solution from each well of the 96-well plate and add it to the hemagglutination plate, then add an equal volume of chicken red blood cells to each well of the hemagglutination plate, place it in a 37℃ incubator for about 20 minutes, observe the hemagglutination situation, and record the hemagglutination titer.
[0066] 5. Calculate the TCID50 of the virus using the Karber method.
[0067] Table 2 TCID of blank control (DMSO) and compound 10 50 value
[0068]
[0069] The TCID50 test results of the supernatant were similar. The average TCID50 value of the DMSO control group was about 1 log higher than that of the compound 10 treatment group, and the difference was significant. (See Appendix Figure 15-16 ).
[0070] This experiment was conducted by a method well known to those skilled in the art, and A549 cells were used to evaluate the cytotoxicity of the compound 10 synthesized by the present invention. The experimental results showed that the cell viability of compound 10 was 90% at a concentration of 500uM, and it had very low cytotoxicity. The in vitro anti-influenza activity of compound 10 was also tested, and the M1 protein with the highest abundance in influenza virus was detected by Western blots to reflect the replication level of influenza virus in cells. The results showed that the M1 protein in the compound 10 treatment group was significantly lower than that in the DMSO control group; the TCID50 test results of the supernatant were similar, and the TCID50 mean of the DMSO control group was about 1 log higher than the mean of the compound 10 treatment group, and the difference was obvious. The present invention has a good application prospect in the preparation and research of anti-influenza virus drugs.
Claims
1. A ribose-adenine dimer prodrug compound, characterized in that: It has the following general structural formula, R 1 and R 2 The same or different, wherein X and Y are independently selected from -NH2, -H; and Z is selected from H, F, Me.
2. The ribose-adenine dimer prodrug compound according to claim 1, characterized in that: in, X is selected from -NH2, Y is selected from -H; and Z is selected from H.
3. The ribose-adenine dimer prodrug compound according to claim 2, characterized in that: Selected from the following compounds: (1)R 1 =R 2 =H;X=NH2,Y=H;Z=H; (2) X=NH2,Y=H;Z=H。 (3) X=NH2, Y=H; Z=H.
4. Use of the ribose-adenine dimer prodrug compound according to claim 1, 2 or 3 in drug preparation, characterized in that: It is used as an active ingredient in the preparation of medicines for treating influenza.
